Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
Tyrosine-protein kinase transforming protein Abl (ABL1)
- Target
- ABL1
- Molecular classification
- Enzyme, Tyrosine Kinase, Non-receptor tyrosine kinase
01
Overview
Tyrosine-protein kinase ABL1, commonly referred to as c-Abl, is a non-receptor tyrosine kinase encoded by the ABL1 gene. It plays a central role in regulating various cellular processes including cell differentiation, division, adhesion, cytoskeleton remodeling, DNA repair, and stress response. A hallmark pathological event involving ABL1 is the t(9;22) chromosomal translocation that fuses BCR with ABL1 to create the BCR–ABL fusion gene, a key driver in chronic myelogenous leukemia (CML) and some cases of acute lymphoblastic leukemia (ALL). Abl has been a major target for selective small-molecule inhibitors such as imatinib for CML therapy.
- Other names
- p150Proto-oncogene tyrosine-protein kinase ABL1Proto-oncogene c-AblJTK7C-ABLAblAbelson tyrosine-protein kinase 1
02
Mechanism of action
Inhibition of ABL1 tyrosine kinase activity
03
Biological functions
Cell differentiationCell divisionCell adhesionCytoskeleton remodelingDNA repairStress responseCell motilityReceptor endocytosisAutophagyDNA damage responseApoptosisT-cell differentiationAxon guidanceCell cycle control
04
Disease associations
Chronic myelogenous leukemiaAcute lymphoblastic leukemiaBreast cancerIschemiaMature B-cell lymphomaCancer
05
Safety considerations
Resistance to inhibitorsOff-target effects
06
Interacting drugs
07
Biomarkers
BCR-ABL fusion gene
Beyond the preview
Go deeper on Tyrosine-protein kinase transforming protein Abl (ABL1).
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Clinical trials
Full profile accessFollow the clinical studies evaluating therapies directed at this target.
- Trial design
- Status
- Readouts
Competitive landscape
Full profile accessCompare approaches across drug candidates, modalities, and indications.
- Programs
- Modalities
- Indications
Literature & evidence
Full profile accessInvestigate the research and source evidence behind target biology and development.
- Publications
- Sources
- Analysis
Patents
Full profile accessExplore patent activity around therapies and technologies addressing this target.
- Patents
- Assignees
- Technologies
Research & analysis
Full profile accessConnect target biology, drug development, and emerging evidence in your research.
- Biology
- Development news
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Tyrosine-protein kinase transforming protein Abl (ABL1).